The Patent Finder

Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb

ZymoGenetics Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 60/758,066, filed Jan 10, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 7,638,126Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb
In force
 · High confidence
ZymoGenetics, Inc.In force
High confidence
US 8,685,395Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells
In force
 · Low confidence
ZymoGenetics, Inc.In force
Low confidence
US 8,974,783Methods of Treating Pain Using an IL-31RA or Osmr-B Antagonist
In force
 · Low confidence
ZymoGenetics, Inc.In force
Low confidence
US 9,334,322Methods of Antagonizing Signal Transduction in Spinal Cord Cells Using an IL-31RA or Osmr-B Antagonist
In force
 · Medium confidence
ZymoGenetics, Inc.In force
Medium confidence
US 9,631,022Method Treating Neuronal Tissue Inflammation Using an IL-31RA Monoclonal Antibody
In force
 · Low confidence
ZymoGenetics, Inc.In force
Low confidence
US 9,828,431Use of IL-31RA Monoclonal Antibodies for Treating Neuronal Inflammation
In force
 · Low confidence
ZymoGenetics, Inc.In force
Low confidence
Application 15/799,445Use of IL-31RA Monoclonal Antibodies for Antagonizing Signal Transduction in Dorsal Root Ganglion Cells
Abandoned
Abandoned Mar 31, 2019
ZymoGenetics, Inc.AbandonedAbandoned Mar 31, 2019
Application 16/227,307Use of IL-31RA Monoclonal Antibodies for Antagonizing Signal Transduction in Dorsal Root Ganglion Cells
Abandoned
Abandoned Mar 16, 2020
ZymoGenetics, IncAbandonedAbandoned Mar 16, 2020
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by ZymoGenetics Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited